ep star align guid par
handili exceed forecast stronger revenu profit
factor line ad ep move
reflect stronger top-line growth trajectori lower tax rate
rais tp higher view
impress top-line experi impress revenu growth
well ahead forecast rise case shipment vs estimate
increas asp vs estimate bright spot includ
sustain momentum teen spike scanner revenu
plan bp flow million facilit
million capit expenditur remain debt free million
reiter outperform share ralli ytd vs
 encourag latest upsid sustain torrid
double-digit growth trajectori initi guidanc call revenu growth
high end lt goal moment
experi rel line consensu expect
despit increment invest spend year still project
industry-lead rise ev/ebitda
share trade premium lead dental implant manufactur straumann
view warrant reflect rapid growth profil
term risk factor clearli competitor wing
recent collabor orthodont digit workflow view
remain well ahead term innov meaning competit
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
manufactur system clear align
therapi intra-or scanner cad/cam digit servic use
dentistri orthodont dental record storag
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
price jan rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
continu churn impress quarter strength across nearli everi line
item offer evid abil sustain double-digit growth trajectori
continu prevail even aggress growth forecast also make
consider stride across under-penetrated elus teen market help
increasingli target advertis effort teen case start strong
y/i heel growth y/i manag also detail dtc initi
expand retail concept four store financ program also
fuel market traction amongst patient practition underappreci dynam
also record number invisalign doctor newli train quarter
help sustain case growth momentum new doctor ad
outsid north america total train date world-wide vs
doctor train world-wide year ago period y/i
remain key sourc growth ou clear align revenu rise
repres case shipment major
record number doctor add also outsid north america
note continu realiz higher averag sell price oversea vs
figur clear align case shipment patient type
guidanc lt project intact preliminari outlook rel line
unveil quarterli ep guidanc came higher consensu
midpoint predic revenu growth vs consensu
also provid preliminari outlook call revenu growth
high end lt rang oper margin flat yoy continu
reinvest busi dynam justifi torrid growth profil note
effect tax rate expect drop vs model much
benefit come result accret
accret overal
importantli longer term year growth aspir remain consist past
disclosur call revenu compound-annual-growth-rate gross margin
territori oper margin free cash flow growth still
expect remain healthi trajectori next year
ttm dso improv sequenti day day expect continu
improv come quarter work erp/system relat
overal thesi remain improv clinic awar consum sentiment
new technolog enhanc expand geograph teen market focu
drive sustain double-digit revenu growth profit rise faster albeit
time scalabl cost base outstand debt enhanc visibl
long-term double-digit ep growth modest capit requir high
rise drive valuat higher
figur doctor train geograph segment
forecast revenu grow billion increas case
shipment ebitda margin declin bp y/i continu invest
go market strategi overal ep rise y/i well major
forecast revenu rise billion driven increas case
shipment estim ebitda margin increas bp y/i oper leverag
higher volum ep increas
ev/ebitda share close premium lead dental implant
manufactur straumann view warrant light continu
abil exceed high expect excel innov increasingli
good sold
sell gener administr
depreci amort
interest expens incom
good sold
sell gener administr
research develop
net incom avail common sharehold
good sold
sell gener administr
net incom avail common sharehold
compani mention price
